Relmada Therapeutics, Inc.
RLMD
$0.39
-$0.0083-2.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 25.86% | 1.25% | 29.78% | 17.07% | 33.68% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -26.58% | -37.43% | -39.66% | -23.66% | 68.52% |
| Change in Net Operating Assets | -46.73% | -48.42% | -1,288.53% | 165.65% | 252.02% |
| Cash from Operations | 14.15% | -43.21% | 0.08% | 21.01% | 71.44% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 46.56% | 318.18% | 1,316.84% | -74.86% | 567.63% |
| Cash from Investing | 46.56% | 318.18% | 1,316.84% | -74.86% | 567.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -75.13% | -- | -- | -- | -126.37% |
| Cash from Financing | -75.13% | -- | -- | -- | -124.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 191.03% | 92.25% | 105.21% | -111.73% | 92.98% |